| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers IB Hilton, AM D'ippolito, CM Vockley, PI Thakore, GE Crawford, TE Reddy, ... Nature biotechnology 33 (5), 510-517, 2015 | 2073 | 2015 |
| Expanded encyclopaedias of DNA elements in the human and mouse genomes JE Moore, MJ Purcaro, HE Pratt, CB Epstein, N Shoresh, J Adrian, T Kawli, ... Nature 583 (7818), 699-710, 2020 | 1265 | 2020 |
| Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements PI Thakore, AM D'ippolito, L Song, A Safi, NK Shivakumar, AM Kabadi, ... Nature methods 12 (12), 1143-1149, 2015 | 993 | 2015 |
| Targeted epigenetic remodeling of endogenous loci by CRISPR/Cas9-based transcriptional activators directly converts fibroblasts to neuronal cells JB Black, AF Adler, HG Wang, AM D’Ippolito, HA Hutchinson, TE Reddy, ... Cell stem cell 19 (3), 406-414, 2016 | 237 | 2016 |
| Direct GR binding sites potentiate clusters of TF binding across the human genome CM Vockley, AM D’Ippolito, IC McDowell, WH Majoros, A Safi, L Song, ... Cell 166 (5), 1269-1281. e19, 2016 | 189 | 2016 |
| Glucocorticoid receptor recruits to enhancers and drives activation by motif-directed binding IC McDowell, A Barrera, AM D'Ippolito, CM Vockley, LK Hong, ... Genome research 28 (9), 1272-1284, 2018 | 111 | 2018 |
| Phosphatidylinositol 3-kinase (PI3K) signaling via glycogen synthase kinase-3 (Gsk-3) regulates DNA methylation of imprinted loci AP Popkie, LC Zeidner, AM Albrecht, A D'Ippolito, S Eckardt, DE Newsom, ... Journal of Biological Chemistry 285 (53), 41337-41347, 2010 | 100 | 2010 |
| Pre-established chromatin interactions mediate the genomic response to glucocorticoids AM D'Ippolito, IC McDowell, A Barrera, LK Hong, SM Leichter, LC Bartelt, ... Cell systems 7 (2), 146-160. e7, 2018 | 99 | 2018 |
| Perspectives on ENCODE MP Snyder, TR Gingeras, JE Moore, Z Weng, MB Gerstein, B Ren, ... Nature 583 (7818), 693-698, 2020 | 96 | 2020 |
| Epidemiology of pediatric holiday-related injuries presenting to US emergency departments A D'Ippolito, CL Collins, RD Comstock Pediatrics 125 (5), 931-937, 2010 | 49 | 2010 |
| Human genome-wide measurement of drug-responsive regulatory activity GD Johnson, A Barrera, IC McDowell, AM D’Ippolito, WH Majoros, ... Nature communications 9 (1), 5317, 2018 | 41 | 2018 |
| Perspectives on ENCODE F Abascal, R Acosta, NJ Addleman, J Adrian, V Afzal, B Aken, JA Akiyama Nature 583 (7818), 693-699, 2020 | 25 | 2020 |
| Genomic signatures of high-altitude adaptation and chromosomal polymorphism in geladas KL Chiou, MC Janiak, IA Schneider-Crease, S Sen, F Ayele, IS Chuma, ... Nature ecology & evolution 6 (5), 630-643, 2022 | 20 | 2022 |
| A long-range flexible billboard model of gene activation CM Vockley, IC McDowell, AM D'Ippolito, TE Reddy Transcription 8 (4), 261-267, 2017 | 16 | 2017 |
| Gene expression profiling in mouse embryonic stem cells reveals glycogen synthase kinase-3-dependent targets of phosphatidylinositol 3-kinase and Wnt/β-catenin signaling pathways CM Bartman, J Egelston, S Kattula, LC Zeidner, A D’Ippolito, BW Doble, ... Frontiers in Endocrinology 5, 133, 2014 | 15 | 2014 |
| Glycogen synthase kinase-3 (Gsk-3) plays a fundamental role in maintaining DNA methylation at imprinted loci in mouse embryonic stem cells GD Meredith, A D'Ippolito, M Dudas, LC Zeidner, L Hostetter, K Faulds, ... Molecular Biology of the Cell 26 (11), 2139-2150, 2015 | 11 | 2015 |
| Author Correction: Expanded encyclopaedias of DNA elements in the human and mouse genomes JE Moore, MJ Purcaro, HE Pratt, CB Epstein, N Shoresh, J Adrian, T Kawli, ... Nature 605 (7909), E3-E3, 2022 | 8 | 2022 |
| From prescription to transcription: genome sequence as drug target C Guo, AM D’Ippolito, TE Reddy Cell 162 (1), 16-17, 2015 | 8 | 2015 |
| Abstract C091: Preclinical evaluation of PK, PD, and antitumor activity of the oral, non-covalent, potent and highly selective CDK7 inhibitor, SY-5609, provides rationale for … LH Johannessen, S Hu, N Ke, A D'Ippolito, N Rajagopal, J Marineau, ... Molecular Cancer Therapeutics 18 (12_Supplement), C091-C091, 2019 | 6 | 2019 |
| 518MO Tolerability and preliminary clinical activity of SY-5609, a highly potent and selective oral CDK7 inhibitor, in patients with advanced solid tumors M Sharma, B Bashir, E Hamilton, D Juric, K Papadopoulos, D Richardson, ... Annals of Oncology 32, S587-S588, 2021 | 5 | 2021 |
